研究单位:[1]Shanghai Miracogen Inc.[2]Fifth Medical Center of PLA General Hospital Beijing, Beijing, China, 100071[3]The Fourth hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050035河北医科大学第四医院
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-low locally advanced or metastatic BC.